Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $2.39 Million |
|---|---|
| Enterprise Value | $3.43 Million |
| Earnings per Share | $-0.97 |
| Beta | 2.23 |
| Outstanding Shares | 1,800,000 |
| P/E Ratio | -3.68 |
|---|---|
| PEG | -7.26 |
| Price to Sales | 0.07 |
| Price to Book Ratio | 0.27 |
| Enterprise Value to Revenue | 0.1 |
| Enterprise Value to EBIT | -4.21 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.37 |
| Debt to Equity | 0.13 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 1.34%▲ 0.66% |
|---|---|
| Total Invested | $54,383▼ 48.59% |
| Investors Holding | 4▼ 2.00% |
Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the internati...